Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PTEN del |
| Therapy | Pictilisib + Vorinostat |
| Indication/Tumor Type | prostate cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PTEN del | prostate cancer | sensitive | Pictilisib + Vorinostat | Preclinical | Actionable | In a preclinical study, GDC-0941 and Zolinza (vorinostat) acted synergistically to inhibit growth of a human prostate cancer cell line harboring a PTEN deletion in culture (PMID: 9661880, PMID: 22693356). | 22693356 9661880 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (22693356) | Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. | Full reference... |
| (9661880) | Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. | Full reference... |